Site search

Clear filter
2813 results for '' found
A randomised double-blinded interventional pilot of Zoely and Zoloft to treat Premenstrual Dysphoric Disorder (ACTRN12623000496617p)
A randomised double-blinded interventional pilot of Zoely and Zoloft to treat Premenstrual Dysphoric Disorder (ACTRN12623000496617p)
/
A Centralized Platform study for Functional High Risk Multiple Myeloma (ACTRN12625000429459)
A Centralized Platform study for Functional High Risk Multiple Myeloma (ACTRN12625000429459)
/
A program of yoga in a randomised control study in people with atrial fibrillation (ACTRN12624000264583)
A program of yoga in a randomised control study in people with atrial fibrillation (ACTRN12624000264583)
/
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic
/
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (NCT05614063)
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (NCT05614063)
/
WITHDRAWal of heart failure directed therapies in recovered Atrial Fibrillation mediated cardiomyopathy- WITHDRAW-AF study (ACTRN12621000896875)
WITHDRAWal of heart failure directed therapies in recovered Atrial Fibrillation mediated cardiomyopathy- WITHDRAW-AF study (ACTRN12621000896875)
/
A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR
A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR
/
A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT05444257)
A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT05444257)
/
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygou
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygou
/
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Mini
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Mini
/
1 2 3 4